DCGI plans survey to detect counterfeit drugs
NEW DELHI: The Drug Controller General of India (DCGI) is planning a survey to detect the quantum of spurious and substandard drugs being sold to unsuspecting customers.The regulator, mandated to look after safety, efficacy of drugs and give marketing approval, plans to cover 61 popular brands of medicines used in nine therapeutic categories including diabetes, tuberculosis and cardiovascular diseases through the study.
By Sushmi Dey
26 July 2008